Upon further examination, we found evidence that the subtype 2 cells may represent a population of malignant plasma cells expressing high levels of PHF19. PHF19 is known to play a role in hematopoietic stem cell state and differentiation [71–73] and is a marker for aggressive disease in MM [70]. This evidence concerns the gene PHF19 and Miyoshi myopathy.